ImmunoMet Therapeutics was founded in 2015 as a spin-off from HanAll Biopharma in Korea, with a focused mandate: develop lixumistat into a cancer drug addressing one of oncology's most stubborn challenges: resistance to existing treatments.
ImmunoMet was founded with a singular focus: develop lixumistat into a validated clinical asset targeting oxidative phosphorylation in cancer. Since 2015, the company has raised approximately $39 million and advanced lixumistat through multiple Phase 1 studies and into a recently completed Phase 1b/2a trial at MD Anderson Cancer Center.
The company works with a network of specialist CROs and clinical partners, each contributing world-class expertise across chemistry, manufacturing, clinical operations, legal, and regulatory functions.
Interim data from the PDAC trial at MD Anderson presented at the ASCO Gastrointestinal Cancers Symposium.
Updated Phase 1b/2a data presented at the ESMO Gastrointestinal Cancers Symposium.
ImmunoMet will present updated data and investment thesis at BIO International 2026, San Diego Convention Center.
A focused team, a best-in-class asset, and a clear path to proof of concept. We'd welcome a conversation.
